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Abstract
Background
Staphylococcus aureus is an important pathogen in cystic fibrosis (CF). However, it is not
clear which factors are associated with worse lung function in patients with persistent S.
aureus airway cultures. Our main hypothesis was that patients with high S. aureus density in
their respiratory specimens would more likely experience worsening of their lung disease
than patients with low bacterial loads.
Methods
Therefore, we conducted an observational prospective longitudinal multi-center study and
assessed the association between lung function and S. aureus bacterial density in
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respiratory samples, co-infection with other CF-pathogens, nasal S. aureus carriage, clinical
status, antibiotic therapy, IL-6- and IgG-levels against S. aureus virulence factors.
Results
195 patients from 17 centers were followed; each patient had an average of 7 visits. Data
were analyzed using descriptive statistics and generalized linear mixed models. Our main
hypothesis was only supported for patients providing throat specimens indicating that
patients with higher density experienced a steeper lung function decline (p<0.001). Patients
with exacerbations (n = 60), S. aureus small-colony variants (SCVs, n = 84) and co-infection
with Stenotrophomonas maltophilia (n = 44) had worse lung function (p = 0.0068; p =
0.0011; p = 0.0103). Patients with SCVs were older (p = 0.0066) and more often treated with
trimethoprim/sulfamethoxazole (p = 0.0078). IL-6 levels positively correlated with decreased
lung function (p<0.001), S. aureus density in sputa (p = 0.0016), SCVs (p = 0.0209), exacer-
bations (p = 0.0041) and co-infections with S. maltophilia (p = 0.0195) or A. fumigatus (p =
0.0496).
Conclusions
In CF-patients with chronic S. aureus cultures, independent risk factors for worse lung func-
tion are high bacterial density in throat cultures, exacerbations, elevated IL-6 levels, pres-
ence of S. aureus SCVs and co-infection with S. maltophilia.
Trial Registration
ClinicalTrials.gov NCT00669760
Introduction
Cystic fibrosis (CF) patients suffer from recurrent bacterial airway infections, which often lead
to respiratory insufficiency and reduced life expectancy [1]. Staphylococcus aureus is one of the
most frequently isolated pathogens from the airways of these patients [2–4]. Recent studies
have shown the importance of S. aureus in young children with CF by way of eliciting an
increased inflammatory response measured in broncho-alveolar lavages [5–9]. Thirty percent
of the general population are persistent nasal carriers of S. aureus and this percentage is even
higher in CF patients [10–12]. Nasal carriers have been shown to have a higher risk for S.
aureus infections, but a lower rate of lethal infections [13]. It is often difficult to decide whether
culturing S. aureus in respiratory specimens from CF patients is merely caused by colonization
or whether this is also associated with worsening lung disease requiring antibiotic treatment.
To support clinical decision, interleukin-6 levels in blood, which have been shown to increase
in CF patients during airway inflammation [14], may serve as a potential marker for severity of
inflammation.
In the present study, our goal was to determine risk factors associated with worse lung func-
tion in CF patients older than six years, who had been persistently colonized by S. aureus. We
thus conducted a prospective observational longitudinal multi-center study (ClinicalTrials.
gov: NCT00669760). We hypothesized that patients with high bacterial loads of S. aureus in
airway specimens were more likely to experience worse lung function compared to patients
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with lower bacterial loads. Secondary objectives were the association between lung function
and S. aureus nasal carriage in CF patients, the role of blood IL-6 levels and IgG levels against
44 S. aureus virulence factors, presence of small colony variants (SCVs) of S. aureus and co-
infection with other CF-related pathogens such as Stenotrophomonas maltophilia, methicillin-
resistant S. aureus (MRSA), Aspergillus fumigatus, Achromobacter xylosoxidans and Mycobacte-
rium abscessus on lung function.
Materials and Methods
Study design
We conducted an observational prospective multicenter study to evaluate risk factors for
worse lung function in patients with persistent S. aureus airway cultures older than 6 years.
The treating physicians recruited CF patients for the study by using the following definitions
for persistence from the medical records: 1. Patients presented with at least 2 positive cultures
6 months apart within one year before recruitment, or 2. half of the respiratory samples the
year before recruitment were S. aureus positiv. The first patient was recruited in June 2008, the
last patient finished the observation period in February 2010. At each visit throat or sputum
cultures were obtained and sent to the central study laboratory located in Mu¨nster, Germany.
On the basis of a study investigating chronic bronchitis patients [15], we hypothesized that
CF-patients with high loads (in sputa1x106CFU/ml; in throat cultures semi-quantitative
score3) of S. aureus in their airway specimens are more likely to experience worsening of
lung disease due to S. aureus than patients with low bacterial loads. To rule out an impact of P.
aeruginosa or Burkholderia cepacia complex (BCC) on lung function, patients with cultures of
these two pathogens were excluded. We defined exacerbation by evaluating clinical symptoms
established by Fuchs et al. for the assessment of exacerbation [16]. If a patient met at least four
out of 11 evaluated symptoms, the clinical status was determined as exacerbation.
Secondary objectives included the association between nasal S. aureus carriage, the level of
IL-6, the presence of S. aureus small colony variants (SCVs) and the co-culture of other impor-
tant CF pathogens such as S. maltophilia, A. xylosoxidans, A. fumigatus and M. abscessus and
the risk for exacerbation or worse lung function.
Inclusion criteria. CF Individuals older than six years were included with persistent S.
aureus airway cultures one year before recruitment.
Enrollment and follow-up. Patients identified as persistently colonized by S. aureus as
defined by our inclusion criteria were enrolled in this study by their attending CF specialists. If
P. aeruginosa or BCC were cultured for more than 6 months during the study period, patients
were excluded from further analysis. Patients were followed for a period of 21 months with
regular visits (usually every 3 months). Sputum samples were spontaneously produced. There
were no requirements for induced sputum cultures. Blood samples were taken from patients
once yearly and/or at exacerbations. An ethical statement was obtained at the main study cen-
ter with the central laboratory in Mu¨nster, Germany (2007-496-f-S). Other ethical statements
have been obtained from the Universita¨tsklinikum Tu¨bingen 450/2008B02, Martin-Luther-
Universita¨t Halle Wittenberg hm/bu, A¨rztekammer Hamburg MC039/09 and the Universi-
ta¨tsklinikum Dresden. All other ethic committees at the Ruhr Universita¨t Bochum, Universi-
ta¨tsklinik Essen, Medizinische Hochschule Hannover, Universita¨tsklinikum Jena, Charite´
Universita¨tsmedizin Berlin, Campus Virchow Klinikum, Kinderkrankenhaus Osnabru¨ck,
Universita¨tsklinik Innsbruck, Universita¨tsklinik Du¨sseldorf, Park Scho¨nefeld Klinik Kassel
and the Universita¨tsklinikum Leipzig waived their approval. Written informed consent was
obtained from all patients and parents, if patients were younger than 18 years. Clinical trial
registered with www.clinicaltrials.gov (NCT00669760).
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Investigated Fuchs criteria and clinical report forms (CRFs) [16]
At every visit patients performed lung function tests assessed as forced expiratory volume in 1
second (FEV1). Other recorded clinical parameters included the presence of fatigue, malaise or
lethargy, sinus discharge, cough and hemoptysis as well as sputum volume or color. These data
were documented by the treating physicians in CRFs, together with CFTR genotype, pancreas
sufficiency/insufficiency, physical and radiographic findings on examination of the chest,
body mass index and antibiotic therapy. The CRFs were sent together with the respiratory
specimens to the central laboratory in Mu¨nster, Germany.
Microbiology
All airway and blood samples obtained from patients were sent to the central study laboratory
(Medical Microbiology, Mu¨nster, Germany) within 24 hours and were cultured according to
standard procedures for CF airway cultures [17,18]. All samples were streaked on Columbia
sheep blood agar (Becton Dickinson, Heidelberg, Germany), MacConkey agar for Gram-nega-
tive bacteria (Becton Dickinson, Heidelberg, Germany), SAID chromogenic agar for S. aureus,
(bioMerieux, Nu¨rtingen, Germany), all incubated for 48h at 37˚C; on chocolate agar (Mast
Diagnostica, Reinfeld, Germany) for Haemophilus influenzae, incubated for 48h at 37˚C with
5% CO2; on BCSA agar (bioMerieux, Nu¨rtingen, Germany) for Burkholderia cepacia complex,
incubated at 30˚C for 10 days, and on Kimmig agar for fungi. In case of mucoid consistency,
sputa were incubated with sputasol (dithiotreitol, Oxoid, Wesel, Germany) for 30 min at 37˚C
and homogenized by vortexing and vigorous pipetting before further processing. Quantitative
cultures of sputa were performed by serial dilution of 500μl of sputum in 4.5ml 0.85% NaCl
according to standard procedures. Semi-quantitative analysis was performed for throat and
nasal cultures and for sputa of less than 500μl sputum. A score of 1 was assigned to single S.
aureus colonies on the primary agar plate, a score of 2 to medium density and a score of 3 to
highly dense numbers of S. aureus colonies on the primary agar plate, respectively. SCVs were
identified by sub-culturing isolates of interest from Columbia blood and SAID agar on Colum-
bia blood agar (incubated at 37˚C) and on Schaedler agar (incubated at 37˚C with 5% CO2) for
24h [19]. All isolates, which displayed small colony size on Columbia blood and normal size
on Schaedler agar were identified as SCVs, which was further confirmed by a positive catalase
and positive Pasteurex Staph Plus test (BIO-RAD, Mu¨nchen, Germany). In case of negative
results, isolates were identified by 16S-RNA sequencing.
Measurements of anti-staphylococcal antibodies
The levels of IgG antibodies against 44 staphylococcal antigens in serum samples of CF
patients and 53 healthy nasal carriers, who consisted of volunteers of the Institute of Medical
Microbiology and medical students, were measured using a bead-based flow cytometry tech-
nique (xMAP1; Luminex Corporation) as previously described [20,21]. All examined antigens
are given in S1 Supporting Material.
IL-6 measurements
IL-6 levels in sera were determined by ELISA (R&D, Wiesbaden, Germany) according to man-
ufacturer instructions and S1 Supporting Material.
Statistical analysis
Patient data were collected longitudinally. The baseline patient characteristics were analyzed
by standard descriptive statistics. Categorical variables were described by absolute and relative
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frequencies. Continuous variables were described by median and range. The following vari-
ables were computed:
Lung function (FEV1% predicted) was determined on the basis of Quanjer et al. [22]. SCV
status (never/ever) of the patients was positive (ever), if SCVs were detected in specimens at
any visit. Carrier status was deemed positive, if in at least at 50% of visits S. aureus nasal car-
riage was detected. Exacerbation status (never/ever) was calculated using the symptoms
defined by Fuchs [16]. A visit with Fuchs score in excess of 4 was defined as an exacerbation
visit. Patients exhibiting at least one exacerbation visit were assigned to the exacerbation ever
group. S. aureus density [sputa: high (<106CFU/ml and low<106CFU/ml according to Mensa
and Trilla for patients with chronic bronchitis;[15] nasal and throat swabs: high >/ = +++;
low + or ++)] was determined based on quantitative and semi-quantitative data per visit.
Patients’ co-infection status (never/ever) with MRSA, S. maltophilia and A. fumigatus was
determined by compiling information from all visits.
Outcome parameters of interest were bacterial density (high/low) in different specimens,
lung function (FEV1% predicted) and interleukin-6 (IL-6) levels.
Cross-sectional analyses, e.g. at baseline, were performed using Mann-Whitney-U tests
from continuous variables and Chi-Squared tests, or Fisher’s exact tests for categorical vari-
ables. Longitudinal analyses were performed to assess the effect of different explanatory vari-
ables on the outcome parameters. To model patient progress over time we used generalized
linear mixed models (GLMM). Bacterial density was modeled by a binary distribution. FEV1%
proved to be normally distributed. IL-6 levels were skewed to the right and a log-normal distri-
bution was used to fit the data. The canonical link function was used. For all models, a random
effect for the individual progress of each patient over the study time (days from first visit) was
included using sp(pow) as covariance structure. All models were age and gender adjusted, if
not otherwise specified. Studentized residual plots were used to examine model requirements.
To analyze the functional dependency of FEV1% on IL-6 levels a polynomial model was
used: FEV1 = β1 × [IL6]β2. The model coefficients were fitted using only baseline measurement
using procnlin in SAS.
Each variable for the specific IgG measurements was tested for normal distribution using
histogram plots, Q-Q plots and the Kolmogorov-Smirnov test. For the comparison of the IgG
levels between patients and healthy controls the multiple testing problem was controlled by
Bonferroni correction. Age and gender adjusted GLMM were used to analyse specific IgG-
responses according to carrier status (yes/no), density (high/low) in sputa, SCV (ever/never)
including a random effect for repeated measurement. q-values were Bonferroni–Holm
adjusted p-values to control the FDR on the multiple significance level of 5%. IgG-levels were
modelled as continuous factors. Odds ratios (OR) were interpreted as a factor, by which the
risk for carriage/high-density/SCV was changed per 100 units in antigen levels. For an associa-
tion of IL-6 and FEV1% predicted with IgG-levels, estimates were interpreted as mean change
in IL-6 per 1 unit in IgG-levels.
The local significance level for all performed tests was α = 0.05. 95%-confidence intervals
are given, where appropriate. Statistical tests are performed exploratory and can be interpreted
as hypothesis generating. Statistical analysis was performed using SPSS (v. 22, IBM) and SAS
(v. 9.4, SAS Institute, Cary, NC).
Results
Demographics and statistics
A total of 195 patients were recruited from 16 German centers and one CF center in Austria,
which take care of 1980 CF patients. Thirteen of 195 patients r were excluded due to the
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chronic culture (> 6 months) of P. aeruginosa (n = 12) or BCC (n = 1) during the study period.
Cystic fibrosis transmembrane regulator (CFTR) genotypes were reported for 173 of 195
patients, see Table 1. Patients with non-p.Phe508del CFTR genotypes (n = 48; 27.7%) were
overrepresented compared to the German CF patient population (Table 1, p<0.0001). The
median age of patients was 16 years (range 5.8 y– 42 y). A preponderance of male to female
subjects compared to the gender ratio of the German CF registry was reported (Table 1,
p<0.001).
The mean number of all visits was seven (range 1–18). Clinical data of patients at baseline
are shown and compared with national data concerning German CF patients in Table 1. Lung
function decline was -1.2717 FEV1% predicted per years of age calculated for the study group
at the first visit (CI -1.6676/-0.7235; p<0.0001).
Age-bacterial density association
For 98 patients at least one sputum (n = 446, range 1–14) was available for analysis, while for
97 patients only throat cultures (n = 663, range 1–11) were available. The age of patients at the
time of the first positive S. aureus sputum culture was significantly associated with S. aureus
density in sputa, indicating that older patients had significantly higher bacterial loads in sputa
compared to younger patients (p = 0.018). Patients with low bacterial density in sputa were on
average 19.2 years of age, while patients with high bacterial loads were 22.2 years of age, respec-
tively. There was no association between age and S. aureus density for patients with only throat
(p = 0.7016) or nasal cultures (p = 0.411).
Bacterial density and lung function
Bacterial density according to specimens is shown in Table 2. No significant association,
adjusted for age and sex, was reported between S. aureus density and FEV1% predicted in nei-
ther patients with sputum (p = 0.5151) nor throat cultures (p = 0.185). There was also no
Table 1. Characteristics of study patients compared to the German CF population.
Study patientsa German CF patients p-value
# of patients 195 4456
Age (in years) 16 (6–42) 20 (6–70) <0.001
Male 120 (61%) 2121 (48%) <0.001
Ex.panc.suff.b 22 (11%) 1426 (32%) <0.001
FEV1 (% predicted) 84.1 (13–121) 72.0 (10–145) <0.001
BMI-quantils 25% (0.07–100%) 27% (0.05–100%) 0.007
Genotypec 173 3832
F508del homod 85 (49%) 1863 (49%) <0.001
F508del heteroe 40 (23%) 1429 (37%)
others 48 (28%) 540 (14%)
aAge, FEV1, BMI and exacerbation numbers are reported as median (range), respectively. Exocrine pancreatic sufficiency and genotype are reported as
absolute frequencies (relative frequencies). We did not exclude one patient, who was 5.8 years at the first visit, but was 6.1 years at the second visit with
seven reported visits throughout the study period.
bexocrine pancreatic sufficiency
cCftr genotype of patients available
dF508del homozygous
eF508del heterozygous
doi:10.1371/journal.pone.0166220.t001
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association of FEV1% predicted with BMI-quantiles for both groups (p = 0.4352; p = 0.1007)
neither at baseline nor during the study period.
However, bacterial density in throat specimens was significantly associated with annual
lung function decline. Patients with high density lost 1.428% FEV1 per year compared to
patients with low density, Fig 1 (0.8626%FEV1; p<0.001 of the interaction of age and density).
We could not observe similar associations with respect to bacterial density in sputum cultures
and lung function decline (data not shown).
The Figs 1–5 show observed FEV1% predicted measurements over study time (days from
first visit). Lines represent the LOESS-fit including 95% confidence intervals of the predicted
values of the generalized linear mixed model.
There was a strong association between FEV1% predicted and bacterial density and cumula-
tive clinical symptoms according to Fuchs criteria [16] for patients who expectorated sputa (95
patients, max. 9 visits; p = 0.0661, S1 Fig), but not for patients with throat cultures (167
patients, max. 9 visits).
Patients with exacerbations have worse lung function
Sixty of 195 patients (31%; 55% male) experienced exacerbations with a mean number of 0.384
exacerbations per patient (range 0, 4). The age distribution of patients with and without
exacerbation did not differ significantly (assessed at baseline, p = 0.5182, S1 Table). Using a
longitudinal multivariable model adjusted for age and sex our data showed that patients with
exacerbations have worse lung function of 5.40% FEV1% predicted (95%CI 1.50 to 9.30
FEV1%) less compared to patients without exacerbations (p = 0.0068, Fig 2). Patients with
exacerbations have a lung function decline per year of age of 1.22% FEV1% predicted (95%CI
0.94 to 1.50 FEV1%) compared to 0.88% FEV1% (95%CI 0.64 to 1.12 FEV1%) predicted in
patients without exacerbations (p = 0.0018). Patients with exacerbations received more antibi-
otics than patients without exacerbations (p = 0.037, OR = 1.175). For patients with exacerba-
tions antibiotic treatment was reported at five visits (mean 4.3), while for patients without
exacerbations at three visits (mean 3.43, p = 0.021), respectively.
Patients with S. aureus nasal carriage
Since persistent nasal S. aureus carriers differ from non-carriers in terms of severe S. aureus
infections [10], we determined the nasal carriage status of our study patients to analyze its
impact on CF lung disease. CF patients with persistent nasal carriage (n = 122, 62.6%) were
more likely male patients compared to patients without persistent nasal carriage (p = 0.00075,
S1 Table) and had significantly more nasal cultures with high bacterial loads (p = 0.0255). S.
aureus nasal carriers had better lung function throughout the study compared to non-carriers
Table 2. Positive airway specimens according to S. aureus density.
Specimens Low density (<1x106CFU/ml) score 1, 2a (%) High density (>/ = 1x106CFU/ml) score 3b (%) Sum
Nasal swabs 517 (68.7) 236 (31.3) 753
Nasal lavage 26 (76.5) 8 (23.5) 34
Throat swabs 545 (69.7) 237 (30.3) 782
Sputa 166 (42.1) 228 (57.9) 394
All 1254 (63.9) 709 (36.1) 1963
alow bacterial density of sputum (<1x106CFU/ml) and throat cultures (score 1 and 2)
bhigh bacterial density of sputum (1x106 CFU/ml) and throat cultures (score3)
doi:10.1371/journal.pone.0166220.t002
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with a difference of 5.758 FEV1% predicted (95%CI 1.84 to 9.68; p = 0.0042; Fig 3). It is note-
worthy that female nasal carriers experienced better lung function throughout the study period
compared to male carriers (p = 0.0064, age-adjusted).
Patients with S. aureus SCVs
To determine the impact of S. aureus SCVs on lung disease data were analyzed in relation to
the culture of SCVs in airway specimens, which were cultured from 84 patients (43%) at least
once. Patients with SCVs were significantly older (p = 0.0066), had lower FEV1% predicted at
baseline (p = 0.0133) and during the study period (p = 0.0337, age and gender adjusted; lower
lung function of 4.099 FEV1% predicted (95%CI 0.32 to 7.88 FEV1%) compared to patients
without SCVs (Fig 4). Within a multivariable model also including antibiotic treatment, the
association of SCVs with worse lung function was still significant (p = 0.0433, lower lung func-
tion in patients with SCVs of 3.89 FEV1% predicted, 95%CI 0.12 to 7.66 FEV1%). In addition,
patients with SCVs were more likely treated with trimethoprim/sulfamethoxazole (TMP/
SMX) compared to patients without SCVs (p = 0.0078).
Fig 1. Patients with throat cultures with high bacterial density experience a more rapid lung function decline. Patients with high
bacterial density in throat specimens are indicated by red squares, patients with low bacterial density in throat specimens by blue circles, the
fitted model prediction is coloured accordingly.
doi:10.1371/journal.pone.0166220.g001
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Patients with co-infecting pathogens
To assess the effect of co-infecting pathogens on lung function, we analyzed data of patients
according to co-infection by important CF pathogens. Patients with S. maltophilia (n = 44)
were more likely female (p = 0.0078), less likely nasal S. aureus carriers (p = 0.0003), more
likely co-infected with SCVs (p<0.0001), experienced more exacerbations (p = 0.0165) and
worse lung function of -3.72% FEV1% predicted throughout the study period (Fig 5,
p = 0.0053, 95%CI -6.33 to -1.10). Patients with A. fumigatus (n = 60) were older (p<0.0001)
and more likely co-infected by SCVs (p = 0.0001).
IL-6 levels
Since interleukin-6 levels have been shown to be helpful as a potential marker for severity of
inflammation [14], we determined IL-6 in sera of the study patients. An inverse association
between IL-6 levels and FEV1% predicted with worse lung function being associated with
higher IL-6 at baseline (p<0.001, Fig 6). IL-6 levels were also associated with S. aureus density
in sputa (p = 0.0016; difference of 0.6031 pg/ml in patients with high versus low S. aureus den-
sity), but not with bacterial density in throat or nasal cultures. Moreover, a significant increase
Fig 2. Patients with exacerbations have worse lung function. Patients with exacerbation are indicated by red squares, patients without
exacerbation by blue circles, the fitted model prediction is coloured accordingly.
doi:10.1371/journal.pone.0166220.g002
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in IL-6 levels in patients with exacerbations (p = 0.0411; difference of 0.2104 pg/ml), SCVs
(p = 0.0209; difference 0.2287 pg/ml), S. maltophilia (p = 0.0195; difference 0.2622 pg/ml) or
with A. fumigatus (p = 0.0496; 0.2256 pg/ml) was documented. In addition, significantly more
CF patients with high bacterial loads displayed elevated IL-6 levels above the upper normal
limit of 12 pg/ml [14,23,24] compared to patients with sputa containing low bacterial loads
(p = 0.0142).
Humoral response towards S. aureus
Recently, the height of S. aureus toxin-specific IgG-levels has been associated with the presence
of S. aureus in airway specimens of CF patients, the severity of exacerbations and with FEV1%
predicted [25]. To expand on these results, we measured IgG-levels against 44 different viru-
lence factors of S. aureus (Supplemental Materials) in single serum samples of 182 CF patients
and included the results in our analysis. Furthermore, IgG-levels of patients were compared to
those of 53 healthy adult volunteers with persistent nasal S. aureus carriage. IgG-levels against
15 out of 44 analyzed antigens were significantly higher in patients compared to controls
(p<0.001, Table 3). It is noteworthy that, IgG-levels against 22 virulence factors were
Fig 3. Patients with S. aureus nasal carriage have better lung function. S. aureus nasal carriers are indicated by blue squares, non-
nasal carriers by red circles, fitted model prediction is coloured accordingly.
doi:10.1371/journal.pone.0166220.g003
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significantly and positively associated with IL-6 levels in all CF patients and, in line with previ-
ous data, IgG-levels against 18 virulence factors were significantly and inversely associated
with FEV1% predicted (S2 Table). A significant positive association between specific IgG-levels
and nasal carriage, presence of SCVs and exacerbations for respectively 14, 16 and 7 antigens
(S2 Table) was reported. Finally, no significant differences were found in IgG-levels of patients
expectorating sputum with high and low bacterial loads (S2 Table).
Discussion
Using a generalized linear mixed model our data only seem to support our main hypothesis
stating that S. aureus density has an impact on lung function for patients who provided throat
swabs since we could show that patients with higher bacterial density in throat cultures experi-
enced a steeper lung function decline compared to patients with low bacterial density in these
airway specimens, Fig 1. However, a closer look at our data showed that this effect was mostly
carried by older patients, who provided throat cultures. The effect was lost, if only the group of
patients younger than 20 years was analyzed, which is why these results should be interpreted
carefully. Yet a trend of worse lung function of patients with high S. aureus density in sputa
compared to patients with low S. aureus density was observed during the study period if cumu-
lative clinical symptoms according to Fuchs were included in the linear mixed model analysis
(p = 0.0661, S1 Fig).
With our inclusion and exclusion criteria a subgroup of patients was selected that differed
from the German CF population by a preponderance of male patients (61.5%) and overrepre-
sentation of non-p.Phe508del CFTR genotypes (27.7%). The fact that our study patients experi-
enced a mean lung function decline of -1.2717 FEV1% predicted per years of age are consistent
Fig 4. Patients with SCVs have worse lung function. Patients with SCVs are indicated by red squares,
patients without SCVs by blue circles, fitted model prediction is coloured accordingly.
doi:10.1371/journal.pone.0166220.g004
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with German registry data that carriers of non-F508del genotypes become later in life colo-
nized with P. aeruginosa than F508del compound heterozygotes and homozygotes and experi-
ence a milder course of the disease[26]. Nevertheless, our study patients still fit into the general
CF-population with a lung function decline of 1 to 3 FEV1% points per year as previously
described [27,28] and do therefore not differ in terms of severity of the clinical disease.
Recently, in a retrospective single center study Ahlgren et al. compared CF patients, who
were colonized with S. aureus or P. aeruginosa only, or neither of these pathogens [29]. In their
study, which also included more male patients (n = 55%), 24% of 84 patients were colonized
by S. aureus [29]. In conjunction with our data this may suggest that male patients are more
likely colonized by S. aureus only and are more likely resistant to colonization or infection
caused by P. aeruginosa.
Several studies have shown that persistent nasal S. aureus carriers are at increased risk for
severe S. aureus infections, but have a survival advantage during sepsis [13]. We thus deter-
mined the impact of nasal S. aureus carriage in CF patients on disease progression. Nasal car-
riage was higher than in other studies assessing nasal carriage as a risk factor for S. aureus
infection [30,31] both in healthy persons [32] and in CF patients [11], but comparable to the
Fig 5. Patients with culture of S. maltophilia have worse lung function. Patients with S. maltophilia are indicated by red squares,
patients without S. maltophilia by blue circles, fitted model prediction is coloured accordingly.
doi:10.1371/journal.pone.0166220.g005
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study of Goerke et al. [11,12]. This is most likely attributable to the pre-selection on the basis
of our inclusion criteria with the requirement of S. aureus persistence in patients’ airways.
During the study period the number of patients experiencing at least one pulmonary
exacerbation was somewhat lower in our study compared to the study by Sanders et al. (31%
versus 40%), who determined the association of frequency of exacerbations and subsequent
lung function decline in more than 8.000 CF patients retrospectively [33]. This observation is
most likely due to the fact that we excluded patients with chronic P. aeruginosa infection who
have been shown to experience a more severe course of disease [34].
Our data thus clearly show that the culture of SCVs was independent of P. aeruginosa co-
infection, but associated with advanced age, lower lung function and treatment with TMP/
SMX at both base line and during the study period. Recently, Wolter et al. showed that the
recovery of SCVs in airway specimens is independently associated with worse lung function in
children [35]. Further studies also indicate that the detection of S. aureus SCVs was associated
with persistence of S. aureus in airway specimens [19], advanced age [36], worse lung function
[35–37] and co-infection with P. aeruginosa [35,36]. However, in our study we ruled out any
impact of P. aeruginosa by excluding patients with persistent P. aeruginosa infection. In future
analyses, it will be investigated if special geno- or phenotypes of S. aureus have an impact on
the clinical status of the patients.
In our study, patients co-infected by S. maltophilia differed from patients without S. malto-
philia. They were most likely female, not S. aureus nasal carriers, co-infected with S. aureus
SCVs and experienced more exacerbations. While Goss et al. [38] did not find any impact of S.
maltophilia on lung function, Waters et al. have recently shown that S. maltophilia represented
Fig 6. Higher IL-6 is associated with lower FEV1% predicted. Scatterplot of baseline measurements (n = 88) of all patients
with blood samples provided at the first visit. The fit line shows the results of a non-linear regression model. Dark shaded areas
show 95% confidence band, lighter shaded area shows 95% prediction band.
doi:10.1371/journal.pone.0166220.g006
Lung Function in CF Patients with S. aureus
PLOS ONE | DOI:10.1371/journal.pone.0166220 November 18, 2016 13 / 18
an independent risk factor for pulmonary exacerbations [39], when patients were persistently
colonized with S. maltophilia. Although we did not distinguish between S. maltophilia cultured
once or persistently, co-infection by S. maltophilia clearly had a negative impact on the clinical
status of our patients.
Also, patients co-infected by A. fumigatus significantly differed from patients without A.
fumigatus with respect to age and prevalence of SCVs. Surprisingly, patients with A. fumigatus
exhibited a better lung function (data not shown) compared to patients without the fungus.
This is in contrast to the results reported by Amin et al. [40] showing worse lung function for
37 out of 230 CF patients with persistent A. fumigatus infection. This discrepancy may be due
to the fact that we did not distinguish between intermittent and chronic infection. It may also
be explained by a sampling effect as we primarily cultured A. fumigatus from a small number
of mostly A. fumigatus-positive older patients.
Recently, Horsley et al. documented IL-6 as a key biomarker of inflammation in CF patients
with exacerbations [14]. We found that IL-6 levels were significantly correlated with S. aureus
density in sputa, and with the presence of exacerbations, SCVs, S. maltophilia or A. fumigatus.
Thus, these results suggest that IL-6 is a highly sensitive marker for lung disease. IL-6 may
potentially be used to identify patients, which might benefit from initiation of antibiotic
therapy.
CF patients mounted higher IgG-levels against numerous virulence factors of S. aureus
compared to healthy controls. Such an immune response against S. aureus is comparable to
those of patients that exhibited S. aureus bacteremia or osteomyelitis [20]. The fact that the
adaptive immune system produces specific antibodies against S. aureus underlines that persis-
tently colonized CF patients are immunologically challenged by S. aureus although these spe-
cific antibodies cannot resolve S. aureus persistence. While no significant association between
Table 3. Significant specific IgG levels against S. aureus antigens in CF patients compared to healthy controls.
Antigen Mean IgG level patients (±
SE)a
Mean IgG level controls (±
SE)a
p valueb,e Correlation coefficient of IgG and IL-6
levelsc
p valued
Efb 4605 (±210) 2089 (±208) < 0.0001 0.010 0.840
Glucosaminidase 14992 (±250) 11567 (±571) < 0.0001 0.147 0.002
HlgB 13621 (±174) 9878 (±407) < 0.0001 0.061 0.197
IsaA 13288 (±413) 10479 (±678) 0.0009 0.207 < 0.0001
IsdA 10701 (±250) 7638 (±429) < 0.0001 0.304 < 0.0001
LukD 14176 (±248) 11485 (±464) < 0.0001 0.14 0.003
LukE 14272 (±238) 11720 (±474) < 0.0001 0.169 < 0.0001
LukF 4079 (±121) 2718 (±243) < 0.0001 0.169 < 0.0001
LukS 14097 (±239) 7134 (±524) < 0.0001 0.206 < 0.0001
LytM 6576 (±308) 3555 (±380) 0.0001 0.27 < 0.0001
Nuc 14405 (±271) 4752 (±493) < 0.0001 0.0837 0.0795
SA0688 3063 (±259) 760 (±116) < 0.0001 0.355 < 0.0001
SSL5 2589 (±128) 1616 (±111) < 0.0001 -0.020 0.669
SSL9 8910 (±194) 7568 (±306) 0.0009 0.079 0.098
Wall teichoic acid 2491 (±124) 319 (±117) < 0.0001 0.109 0.025
aAverage IgG levels are given in mean fluorescence activity (MFI).
bp-values of difference between 190 patients and 53 healthy controls (Mann-Whitney U test)
cSpearman’s rank correlation coefficients were calculated for IgG- and IL-6 levels in all patients.
dp-values of correlation between IgG and IL-6
eadjusted p-values (Bonferroni correction)
doi:10.1371/journal.pone.0166220.t003
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bacterial density in airway specimens of CF patients and IgG-levels was reported, we found a
significant association of many specific IgG-values with IL-6-levels, worse lung function, nasal
carriage and the culture of SCVs. The latter confirms and expands on another recent study
that demonstrated a significant inverse association between S. aureus toxin-specific IgG-levels
and lung function in CF patients [25]. In contrast to our results, this previous study also
showed a significant association between the culture of S. aureus in airway specimens and IgG-
levels, albeit bacterial density was not quantified as it was done in our study.
There are several limitations to our study. First, our inclusion and exclusion criteria
selected a sub-group of CF patients, which do not reflect the entire CF population. However,
lung function data of our patients were comparable to other studies [27,41]. Our data
should thus provide meaningful results for the general CF population. Second, our selected
patient group did experience somewhat less exacerbations compared to groups with P. aeru-
ginosa infection, which makes it more difficult to detect significant clinical differences
between groups using exacerbation as an outcome measure. Third, the technique of obtain-
ing throat swabs in the different centres by different nurses or physicians could have influ-
enced the microbiological results of the throat swab cultures. Fourth, it seems that our study
was underpowered to show significant results for the association between S. aureus density
and worse lung function of patients, who were able to expectorate sputum. Since S. aureus is
the most prevalent CF-related pathogen in children, we included patients in our study who
were not able to expectorate sputum. We hypothesized that the determination of bacterial
densities would be of equal value for throat swabs and sputa. Our patient number calcula-
tion was based on this hypothesis. However, there was no association between bacterial den-
sity and lung function for patients with throat swabs, but a trend for patients with high
bacterial density in sputa if cumulative clinical symptoms for exacerbation were included in
the analysis (0.0661, S1 Fig).
To conclude, our results suggest that the presence of exacerbations, non-nasal S. aureus car-
riage, female gender, the presence of S. aureus SCVs, co-infection with S. maltophilia or spe-
cific anti-staphylococcal IgG- and IL-6 levels are independent risk factors for worse lung
function in CF patients with persistent S. aureus infection. Our findings may help to identify S.
aureus patients at risk for more severe airway infections resulting in worse lung function and
will be of value for designing future prospective studies to guide antibiotic therapy in patients
chronically infected with S. aureus.
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